The lethal effect of bis-type azridinylnaphthoquinone derivative on oral cancer cells (OEC-M1) associated with anti-apoptotic protein bcl-2

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 1, 2006, Pages 263-272

  Peng, Yi Chen ^a   Kuo, Hsien Shou ^b   Tsai, Hsin Da ^b   Yang, Yu Ping ^b   Lin, Yuh Ling ^a  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bis type aziridinylnaphthoquinone; Cell cycle arrest; Oral cancer cells (OEC M1); p53 protein

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; 2 AZIRIDIN 1 YL 3 [[2 [2 [(3 AZIRIDIN 1 YL 1,4 DIOXO 1,4 DIHYDRONAPHTHALEN 2 YL)THIO]ETHOXY]ETHYL]THIO]NAPHTHOQUINONE; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; CASPASE 3; CYCLIN B; DIAZIQUONE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL DEATH; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; LC 50; MOUTH CANCER; PROTEIN CONTENT; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

APOPTOSIS; BISBENZIMIDE; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL CYCLE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; MOUTH NEOPLASMS; NAPHTHOQUINONES; PROTO-ONCOGENE PROTEINS C-BCL-2;

ANIMALIA;

EID: 27744561767     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.08.027     Document Type: Article

References (50)

1. D.M. Parkin, P. Pisani, and J. Ferlay CA Cancer J. Clin. 49 1999 33
2. K. Annertz, H. Anderson, A. Biorklund, T. Moller, S. Kantola, J. Mork, and J.H. Olsen Int. J. Cancer 101 2002 95
3. D.M. Walker, G. Boey, and L.A. McDonald Pathology 35 2003 376
4. M.D. Mignogna, S. Fedeles, and L.L. Russo Eur. J. Cancer Prevent. 13 2004 139
5. J. Mork Anticancer Res. 18 1998 3705
6. J. Mork, S. Thoresen, H. Faye-Lund, F. Langmark, and E. Glatter APMIS 103 1995 375
7. J. Sudbo, M. Bryne, L. Mao, R. Lotan, A. Reith, W. Kildal, B. Davidson, T.M. Soland, and M. Lippman Oral Oncol. 39 2003 749
8. S.M. Lippman, J. Sudbo, and W.K. Hong J. Clin. Oncol. 23 2005 346
9. M.B. Sporn, and N. Suh Nat. Rev. Cancer 45 2002 1
10. J.M. Brown Cancer Biol. Ther. 1 2002 453
11. J.M. Brown, and A.J. Giaccia Cancer Res 58 1998 1408
12. B.G. Wouters, S.A. Weppler, M. Koritzinsky, W. Landuyt, S. Nuyts, J. Theys, R.K. Chiu, and P. Lambin Eur. J. Cancer 38 2002 240
13. A.M. Shannon, D.J. Bouchier-Hayes, C.M. Condron, and D. Toomey Cancer Treat. Rev. 29 2003 297
14. M.A. Naylor, and P. Thomson Mini-Rev. Med. Chem. 1 2001 17
15. R.M. Phillips, A.M. Burger, P.M. Loadman, C.M. Jarrett, D.J. Swaine, and H.H. Fiebig Cancer Res. 60 2000 6384
16. J.Y. Kim, C.H. Kim, I.J. Stratford, A.V. Patterson, and J.H. Hendry Int. J. Rad. Oncol. Biol. Phys. 58 2004 376
17. B.G. Siim, F.B. Pruijn, J.R. Sturman, A. Hogg, M.P. Hay, J.M. Brown, and W.R. Wilson Cancer Res. 62 2004 736
18. W.B. Mattes, J.A. Hartly, and K.W. Kohn Biochim. Biophys. Acta 868 1986 71
19. P.S. Lin, K.C. Ho, and S.J. Yang Cancer Lett. 105 1996 249
20. A.E. Lee, and W.R. Wilson Toxicol. Appl. Pharmacol. 163 2000 50
21. E. Smitskamp-Wilms, G. Giaccone, H.M. Pinedo, B.F.A.M. Laan, and G. Peters Br. J. Cancer 72 1995 917
22. S. Danson, T.H. Ward, J. Butler, and M. Ranson Cancer Treat. Rev. 30 2004 437
23. P. Workman, and M.I. Walton G.E. Adams A. Breccia E.M. Fielden P. Wardman Selective Activation of Drug by Redox Processes 1990 Plenum Press New York 173
24. L. Szmigiero, and K.W. Kohn Cancer Res. 44 1984 4453
25. D. Siegel, N.W. Gibson, P.C. Preush, and D. Ross Cancer Res. 50 1990 7293
26. S. Basu, J.E. Brown, G.M. Flannigan, J.H. Gill, P.M. Loadman, S.W. Martin, B. Naylor, A.J. Scally, J.M. Seargent, T. Shah, R. Puri, and R.M. Phillips Int. J. Cancer 109 2004 703
27. S.T. Huang, H.S. Kuo, C.M. Lin, H.D. Tsai, Y.C. Peng, C.T. Chen, and Y.L. Lin AntiCancer Drug Des./Oncol. Res. 11 2003 199
28. S.T. Huang, H.D. Tsai, H.S. Kuo, Y.P. Yang, Y.C. Peng, and Y.L. Lin ChemBioChem 5 2004 797
29. S. Rockwekll, A.C. Sartorelli, M. Tomasz, and K.A. Kennedy Cancer Metastasis Rev. 12 1993 165
30. K.O. Hicks, B.G. Siim, F.B. Pruijn, and W.R. Wilson Radiat. Res. 161 2004 656
31. A.M. Rauth, R.S. Marshall, and B.L. Kuehl Cancer Metastasis Rev. 12 1993 153
32. M. Scheer, A.C. Kuebler, and J.E. Zoller Onkologie 27 2004 187
33. S. Hsu, B. Singh, and G. Schuster Oral Oncol. 40 2004 461
34. S. Koontongkaew, L. Chareonkitkajorn, A. Chanvitan, M. Lee-lakriangsak, and P. Amornphimolttham Oral Oncol. 36 2000 334
35. C.A. Schmitt, and S.W. Low J. Pathol. 197 1999 127
36. G.L. Evans, and K.H. Vousden Nature 411 2001 342
37. K.F. Pirollo, K.B. Bouker, and E.H. Chang Anti-Cancer Drugs 11 2000 419
38. K. Nylader, E. Dabelsteen, and P.A. Hall J Oral Pathol. Med. 29 2000 413
39. R. Kaul, S. Mukherjee, F. Ahmed, M.K. Bhat, R. Chhipa, S. Galande, and S. Chattopadhyay Int. J. Cancer 103 2003 606
40. A.L. Gartel, I.L. Feliciano, and A.L. Tyner Oncol. Res. 13 2003 405
41. N.G. Nikitakis, J.J. Sauk, and S.I. Papanicolaou Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodo. 97 2004 476
42. S.J. Korsmeyer Trends Genet. 11 1995 101
43. D.W. Nicholson Cell Death Differ. 6 1999 1028
44. M.G. Grutter Curr. Opin. Struct. Biol. 10 2000 649
45. G. Salvesen, and V. Dixit Cell 91 1997 433
46. P.A. Amstad, H. Liu, M. Ichimiya, I.K. Berezesky, B.F. Trump, I.A. Buhimschi, and P.L. Gutierrez Redox. Rep. 6 2001 351
47. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd J. Nat. Inst. 82 1990 1107
48. C. Dive, C.D. Gregory, D.J. Phipps, D.L. Evans, A.E. Miliner, and A.L. Wyllic Biochim. Biophys. Acta 1133 1992 275
49. B.A. Komoriya, B.Z. Packard, M.J. Brown, M.L. Wu, and P.A. Henkart J. Exp. Med. 191 2000 1819
50. E.O. Ngo, L.M. Nutter, T. Sura, and P.L. Gutierrez Chem. Res. Toxicol. 11 1998 360